Published on 01/04/25 in the following categories Antimicrobials
Once upon a time, the English bacteriologist Ernest Hankin demonstrated for the first time the presence of anti-bacterial entities in the waters of Indian rivers, putting humanity on the path to a promising anti-infectious therapy that is more relevant than ever.
Let’s go back to 1896, on the banks of the Gange, where cholera is ravaging. Hankin, who had been sent to work on the cholera bacillus, was surprised by the small quantity of Vibrio cholerae in the river. He also wondered why, when cholera broke out on the banks, it did not go down to the villages downstream. Since the disease is carried by water, its spread should follow the river. Hankin then revealed the existence of a substance that, even after passing through a Chamberland filter, attacked the bacteria responsible for cholera with formidable efficiency.
This curiosity called out to Félix d’Hérelle, a French researcher who, identified biological entities capable of forming lysis patches on bacterial cultures, in 1917. He simply named these bacteria eaters: “bacteriophages“. The researcher immediately considered using them to treat bacterial infections, and in 1919, he treated a patient suffering from dysentery: phagotherapy was born.
But what was behind these bacteria killers?
It was not until the 1940s that bacteriophages were observed with an electron microscope. Molecular biology then made it possible to discover that they were encapsidated viruses that only attacked bacteria in a very specific and targeted manner. Moreover, it turned out that bacteriophages can be found in all biotopes, even more so if the environment is rich in bacteria, such as soil or sewage. The latter are nowadays privileged places of supply for researchers.
But why has the use of phagotherapy not become more widespread?
To understand this, let’s go back to the 1930s, when the first antibiotics were developed. The widespread use of these very effective molecules in the Western world simply made bacteriophages fall into oblivion…
Today, due to the uncontrolled use of antibiotics, we must face the challenge of antibiotic resistance. The identification of alternative therapies is therefore essential, and it is quite natural that we are once again turning our attention to phagotherapy. Thus, more than a hundred years after their discovery, bacteriophages will finally be able to play their role and express their full potential, providing humanity with a way to avoid returning to a pre-antibiotic era with disastrous consequences.
News and articles
Management of Microbiological Contamination: Identifying, Understanding and Preventing Recurrence
Microbiological contamination is not limited to a non-compliant result. In R&D development, quality control, an industrial process or biological production, it immediately raises concrete questions: where does the contaminant come from, is it isolated or recurrent, what is its impact, and how can its reappearance be prevented?
The response is not simply to identify the bacterium and then restart the process. To achieve lasting control of bacterial contamination, the investigation must be able to connect laboratory observations with the real operational context: samples, flows, raw materials, equipment, cleaning, disinfection and field practices.
At Smaltis, we approach these situations as a structured microbiological investigation: understanding the problem, isolating the contaminants, identifying and comparing the isolates, preserving useful material, and then testing appropriate prevention solutions.
Skin Microbiome: Cultivating Rigor to Objectify Innovation
The skin microbiome is not mere scenery. It is a functional component of the skin, involved in protection against pathogens, immune dialogue, and the modulation of inflammation. It is a dynamic ecosystem shaped by subtle interactions between bacteria, yeasts, the host, and the environment.
Our approach is grounded in a simple conviction: understanding a microbiome is not merely about identifying it. It is about knowing how to culture it, interrogate it, and generate scientifically defensible data.
This is precisely how we approach the skin microbiome: as a complex ecosystem whose actors, dynamics, and mechanisms must be mastered before attempting to modulate its balance.
Once upon a time, in the hospitals of the twenty-first century, there was an infection that even antibiotics could no longer silence. An opportunistic infection caused by a bacterium called Clostridioides difficile, it often appeared in patients who were already vulnerable… and, above all, already heavily treated. Let us look back at the history of this infection, which gave rise to new therapeutic approaches.
Probiotic Characterization: Demonstrating Safety and Substantiating Activity
Probiotics are often presented as a simple category. In reality, their characterization has become a demanding scientific and regulatory exercise. It is no longer enough to identify a species or to invoke a favorable history of use: the demonstration must now be conducted at the strain level, in a way that is consistent with the intended use, the target population, and the applicable regulatory framework. In the main reference frameworks, a microorganism can be qualified as a probiotic in the strict sense only if it is sufficiently characterized, safe for its intended use, alive at a relevant dose until the end of the product’s shelf life, and associated with a documented health benefit. [1,5,7,8]
The key question therefore becomes: what can we robustly demonstrate about its identity, safety, and functional activity? This is particularly true for new or poorly documented strains, for which taxonomy alone is not sufficient. The EFSA, GRAS, and Canadian frameworks converge on one central point: useful characterization is strain-level characterization interpreted in light of the final use. [1-6]
Designing Bacterial Mutants: From Gene Editing to Robust Strain Engineering
The construction of bacterial mutants is a cornerstone of microbiology. Historically used to decipher gene function, it now plays an equally strategic role in bioproduction, biotechnology, and the development of therapeutic bacteria, where the engineered strain itself may ultimately become the final product.
This shift has profoundly changed how mutagenesis projects are approached. Today, the objective is no longer simply to modify a gene, but to design a strain aligned with its final application, operational constraints, and regulatory expectations.
Lugdunin: the secret weapon of an indomitable bacterium
Once upon a time, an invisible battle was raging deep inside our noses. A microscopic battlefield, where bacteria fought relentlessly to defend their territory. Picture a small village of indomitable Gauls, surrounded on all sides… but instead of Romans, it’s microbes. And in this surprisingly strategic setting, a most unexpected antibiotic was discovered: lugdunin.
2026: Taking on New Scientific Challenges Together
As we step into 2026, the entire Smaltis team sends you our warmest wishes. May this new year bring clarity, creativity, meaningful collaborations — and a few scientific breakthroughs that get the attention they deserve.
Antimicrobial activity testing: measuring, understanding, and anticipating resistance
Every day, antimicrobials face their natural adversaries: bacteria.
But in this silent war, nothing remains static — bacteria learn, adapt, defend themselves… and develop increasingly sophisticated resistance mechanisms.
Smaltis is a microbiology CRO specialized in the study of antimicrobial resistance and the preclinical development of antimicrobials.
We support the developers of new antibiotics, peptides, biocides, and other anti-infective agents with a comprehensive panel of in vitro assays designed to meet the most demanding R&D challenges.
Smaltis at the Key Industry Events of Autumn 2025! From medical devices to biotherapies, from fundamental research to industrial production, we meet project leaders to better understand microbiology needs and build new collaborations.
New Offer Structure: 2 Business Units Supporting Your Projects
At Smaltis, our ambition remains unchanged: bringing microbiological excellence to your innovations.
To better address the diversity of your needs, we have structured our offer around 2 complementary Business Units, true pillars of our scientific and technical commitment.
All articles